Abbott Laboratories (NYSE:ABT - Get Free Report) announced a quarterly dividend on Thursday, September 17th. Stockholders of record on Thursday, October 15th will be paid a dividend of 0.63 per share by the healthcare product maker on Monday, November 16th. This represents a c) dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th.
Abbott Laboratories has increased its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 54 years. Abbott Laboratories has a dividend payout ratio of 44.4% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Abbott Laboratories to earn $6.08 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.4%.
Abbott Laboratories Stock Performance
NYSE:ABT opened at $102.20 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market cap of $176.84 billion, a P/E ratio of 33.07, a PEG ratio of 1.90 and a beta of 0.59. The business's 50-day moving average price is $106.18 and its two-hundred day moving average price is $99.38.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.
About Abbott Laboratories
(
Get Free Report)
Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.
The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.